Press Enter to search · Esc to close
AstraZeneca's once-daily small molecule posts placebo-controlled weight-loss data in The Lancet — and hints at a future where the obesity revolution doesn't require a needle.
A massive new target-trial emulation hints that semaglutide and tirzepatide may do more than shrink waistlines — they may quietly cut the odds of obesity-driven cancers. Here's what the data actually say.
A once-daily oral GLP-1, fresh data linking the class to lower lumbar disease risk, and a network meta-analysis hinting at a nuanced colorectal cancer question. Here's what the moderate evidence actually says.
New research in young adults links long-term obesity to measurable biological aging — and points to metabolism as the load-bearing pillar of longevity.
A new phase 3 trial shows a once-daily pill can deliver meaningful weight loss without a needle — and that small detail could change who actually gets treated.
A wave of head-to-head trials and a biased-agonist newcomer show the GLP-1 class is fragmenting into distinct molecules with measurably different profiles.
A new gene-metabolite map suggests incretin-pathway drugs act on a web of cardiovascular and metabolic systems — not just glucose. Here's what that means for patients in 2026.
New research is beginning to explain why GLP-1 drugs work brilliantly for some and modestly for others — and what comes after the first generation of blockbusters.
A new scoping review reframes obesity as an organelle-level problem — and points to the levers, lifestyle and pharmacological, that actually shift mitochondrial function.
As the GLP-1 class expands beyond weekly injections, three new studies sketch a more complicated risk-benefit map than the headline weight-loss numbers suggest.